Back

What is the evidence for SGLT2 inhibitors in HF?

28 August 2022 (15:35 - 15:45)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in practice (part 4): initiating heart failure treatment in hospital Chronic Heart Failure, Other Open Access ESC Congress 2022

About the speaker

Photo
Professor Piotr Ponikowski

Wroclaw Medical University, Wroclaw (Poland)

4 More presentations in this session

Presentation thumbnail
Introduction and recap.
Professor J. Butler (Dallas, US)
Slides Video
Presentation thumbnail
Implementing in-hospital initiation of an SGLT2 inhibitor in my practice.
Doctor M. Costanzo (Naperville, US)
Slides Video
Presentation thumbnail
Panel discussion.
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
SGLT2 inhibitors in practice: what are the next steps?
Professor S. Anker (Berlin, DE)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in practice (part 4): initiating heart failure treatment in hospital
Video

The Event

Event poster

ESC Congress 2022

28 August 2022 15:35 CET
You may be interested in
thumbnail
Congress Session
SGLT2 inhibitors across the spectrum of heart failure
21 May 2022
thumbnail
Congress Presentation
The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial
25 August 2023
thumbnail
Congress Presentation
Acute hospitalised heart failure: SGLT2 inhibitors.
26 August 2022
thumbnail
Congress Presentation
What value do SGLT2 inhibitors offer to patients hospitalised for heart failure?
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources